Deng et al. retrospectively analyzed 203 NSCLC patients who were treated with first-line generation EGFR tyrosine kinase inhibitors and evaluated the prognostic value of SII, NLR, and PLR. Here, EGFR is linked to non-small cell lung carcinoma.